AnalystBro Research
Research
Company valuation reports, peer comparisons, results notes, industry reports and macro views, built from company filings and official data and independently reviewed before publishing. Company reports show their full model as view-only sheets. Facts and estimates, not investment advice.
2 articles.
Bangladesh All Bangladesh research →
Company · DSE:IBNSINA · Pharmaceuticals & healthcare · Analysis · 29 Oct 2026
IBN SINA Pharmaceutical: 9M FY2026 sales up 18% as the Mawna plant lifts capital work-in-progress to BDT 4.1bn, funded mostly with debt
Sales rose every year for ten years, at 4.5-24.6% a year, with steady 40-42% gross margins; selling and distribution takes 30% of revenue, so ROE fell from 24-25% to 17% in FY2025. The FY2026 cash dividend is 77%, the highest yet.
Company · DSE:BERGERPBL · Chemicals · Initiation · 29 Oct 2026
Berger Paints: 10% annual growth and a 24% ROE support BDT 509–1571 a share
Fair value BDT 509–1571; base 1129, probability-weighted 1,084. Price BDT 1,449 on 29-Oct-2026. Price rises lifted H1 FY2027 EPS to BDT 52.79; the BDT 11.84bn Mirsarai plant, TiO2 and solvent costs, the taka and supplementary duty decide FY2028–29.
Fair value ৳509–1,571 · price ৳1,449.00 (2026-10-29)